Leading the way to a cure


Accelerating Medicines Partnership (AMP)

The Alliance for Lupus Research (ALR) and the Lupus Research Institute (LRI) are proud to join the National Institutes of Health (NIH) in the Accelerating Medicines Partnership (AMP) to speed new paths to treatment for lupus and autoimmune disease.

The new $230 million collaboration will harness the collective knowledge and resources among the NIH, biopharmaceutical companies, nonprofit organizations and academic communities. Recognizing that no new targeted therapies exist for severe lupus, the new consortia will work to better understand the disease and uncover new targets for drug development. A total of $41.6 million is allocated specifically to the autoimmune diseases lupus and rheumatoid arthritis.

As members of the consortium steering committee for lupus and rheumatoid arthritis, LRI and ALR will have an active role in setting the research agenda and assessing progress.

Click for more information on this partnership: http://www.nih.gov/science/amp/autoimmune.htm

Lupus Insight Prize

The annual Lupus Insight Prize, presented in a collaboration among the Alliance for Lupus Research (ALR), the Lupus Foundation of America (LFA), and the Lupus Research Institute (LRI) will be awarded by the three organizations to recognize and honor an outstanding investigator with a documented record of creativity, innovation, and productivity. The researcher will also be someone who has made a novel insight in an area of research that is applicable to the pathogenesis or treatment of lupus and is judged to have a high likelihood of generating further advances by applying that insight to lupus.

The Lupus Insight Prize recipient will be awarded $200,000 to be used for research dedicated to advancing understanding of the genetic, environmental, molecular, immunologic or cellular aspects of lupus and/or its treatment. The Prize must be utilized within three years from the date it is awarded.

Nominations will be reviewed by members of an independent Selection Committee comprised of representatives of the three funding lupus organizations. The Committee will review nominations and award the Prize based on a variety of criteria, including academic achievements, creativity, insight, and potential for future advances that will impact people with lupus.

Click for more information on this partnership: http://www.lupusinsightprize.org/

LRxL-STAT (Lupus Rx List-SLE Treatment Acceleration Trials)

The Alliance for Lupus Research (ALR) and the Lupus Research Institute (LRI) have partnered on a trailblazing cooperative project with AMPEL BioSolutions (Dr. Peter Lipsky & Dr. Amrie Grammer) to speed up the identification and availability of new treatments for lupus. This new effort is focused on identifying new treatments for lupus from among those that have been approved for other human conditions.

This collaborative project will produce a comprehensive evidence-based analysis to fully document and prioritize each as a potential lupus therapy based on mechanism of action, safety profile, availability, feasibility to carry out a trial in lupus, and likelihood to succeed. A panel of academic and industry experts has reviewed the results of the study recommended high priority potential therapies. The top candidates will then be  highlighted for further study in small focused science-rich clinical trials. The study process and analysis will be fully transparent throughout; and the resulting priority list of candidate drugs and treatments will be made widely available for use across the lupus community to advance testing of potential new treatments in lupus.

Click for more information on this partnership: http://www.linkedin.com/in/lrxlstat

Pfizer’s Centers for Therapeutic Innovation (CTI)

Alliance for Lupus Research (ALR) and Pfizer’s Centers for Therapeutic Innovation (CTI) are partnering to discover new therapies for patients living with lupus.  As part of this first-of-its-kind collaboration in lupus, ALR and CTI are co-funding novel translational research projects primarily driven by leading academic medical centers within the CTI network.  Grants for large-molecule projects have been awarded for up to two years for a maximum of $500,000. Small-molecule grants are also being considered.

CTI provides foundations with an opportunity to leverage their resources with those of the pharmaceutical industry to target therapeutics in a specific disease area.  The first foundation partnership signed by CTI was with the ALR and announced in November 2012. CTI and its foundation partners share equal decision-making rights, including selecting projects to incorporate into CTI’s pipeline and evaluation of project progress.

CTI’s goal and that of the ALR in this partnership is the same – to provide new, targeted therapies to patients living with lupus. Our hope is that by combining our resources we can speed the creation of life-saving treatments for patients who need them.

Click for more information on this partnership: https://www.pfizercti.com/partner_with_us/foundations

Click here for information about what Pfizer’s Centers for Therapeutic Innovation looks for in a project.

1.5 million

people in the U.S. have Lupus.

172 million

dollars committed to lupus research by the Lupus Research Alliance.

We're walking across the United States to raise awareness and funds for lupus research.


Show your support by visiting the Lupus Research Alliance online store. Discover the perfect gift, or prepare for a walk with our selection of apparel and accessories.

Powered by Blackbaud
nonprofit software